HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): Georg M. Salzer Ludwig C. Müller Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Salzer, G. M. Articles by Ebner, I. Search for Related Content PubMed PubMed Citation Articles by Salzer, G. M. Articles by Ebner, I.

Ann Thorac Surg 1990;49:759-762
© 1990 The Society of Thoracic Surgeons

---

Articles

Operation for N2 small cell lung carcinoma

Division of Thoracic Surgery, Department of Surgery II, Policlinic for Hematology and Oncology, Department of Internal Medicine, and Department of Radiotherapy, University of Innsbruck, Austria

Accepted for publication December 8, 1989.

^_* Address reprint requests to Dr Satzer, Division of Thoracic Surgery, Department of Surgery II, Anichstrasse 35, A-6020 Innsbruck, Austria.

Of 48 patients with limited small cell lung carcinoma treated by different modes, but always including radical operation, a series of 25 patients with N2 lymph node metastases is reported. In a first period (1970 to 1977) treatment consisted solely of radical resection in 3 patients; chemotherapy was added to operation in 6, and local radiotherapy was added in 2. Since 1977, 14 patients were treated according to a comprehensive therapy protocol including radical resection (six pneumonectomies, one bilobectomy, seven lobectomies), chemotherapy, local radiotherapy, and prophylactic cranial irradiation. Eleven patients, in whom N2 disease was confirmed preoperatively, received chemotherapy as the first step, followed by "adjuvant" resection. Projected 5-year survival rate is 25% for the entire N2 group and 47% for the comprehensively treated group. Seven patients of this latter group are alive 12, 19, 30, 48, 66, 73, and 74 months after comprehensive therapy, equivalent to an observed 2-year survival rate of 38%. This is the largest reported series of patients with resected small cell lung carcinoma in the N2 stage treated at a single institution; the results are so encouraging that we can no longer advocate general refusal of radical lung resection for small cell lung carcinoma in the N2 stage if it is part of a multimodal therapentic protocol.

This article has been cited by other articles:

				T. Lewinski, M. zulawski, C. Turski, and A. Pietraszek Small cell lung cancer I-III A: cytoreductive chemotherapy followed by resection with continuation of chemotherapy Eur J Cardiothorac Surg, August 1, 2001; 20(2): 391 - 398. [Abstract] [Full Text] [PDF]

				L. C. Muller, G. M. Salzer, H. Huber, C. Prior, I. Ebner, H. Frommhold, and H.-W. Prauer Multimodal therapy of small cell lung cancer in TNM stages I through IIIa Ann. Thorac. Surg., September 1, 1992; 54(3): 493 - 497. [Abstract] [PDF]

				P. A. Bunn Jr Operation for stage IIIa small cell lung cancer? Ann. Thorac. Surg., May 1, 1990; 49(5): 691 - 691. [PDF]

				R. J. Ginsberg Operation for small cell lung cancer--Where are we? Ann. Thorac. Surg., May 1, 1990; 49(5): 692 - 693. [PDF]